Compared to local BC samples in the previous study, in our study, we observed the proportion of tissue samples carrying CTCF mutations was higher in the baseline cohort, in which all patients ultimately experienced metastasis (11.43% [4/35] vs. 0.86% [39/4512], P < 0.01). This evidence concerns the gene CTCF and breast cancer.